NEW YORK, NY--(Marketwire -02/21/12)- While the North American economy continues to stagnate, the obesity epidemic in the United States and Canada shows no signs of slowing. According to ObesityEpidemic.org, the statistics show that roughly 33% of the US population is obese and 67% of the US population is overweight. According to The Obesity Research Journal, by 2030, 86.3% adults will be overweight or obese and 51.1% will be obese. Looking to combat North America's growing obesity crisis -- and capitalize on a highly lucrative sector -- several biotechnology firms have been working to develop obesity drugs and treatments. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Vivus, Inc. (NASDAQ: VVUS - News) and Allergan, Inc. (NYSE: AGN - News). Access to the full company reports can be found at:
Vivus, Inc. is engaged in development and commercialization of therapeutic drugs for large underserved markets, including obesity and related morbidities, such as sleep apnea and diabetes and men's sexual health. The FDA had rejected Vivus' diet pill Qnexa in October 2010. Vivus has resubmitted the drug with additional follow-up information, hoping for a more favorable ruling.
Earlier this month Federal health officials announced they still have safety concerns about an experimental diet pill from Vivus. Qnexa is a combination of two older drugs, the Associated Press reports -- the amphetamine phentermine, which is approved for short-term weight loss, and topiramate, an anticonvulsant drug sold by Johnson & Johnson as Topamax.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. Allergan's LAP-BAND Adjustable Gastric Banding System is the first adjustable medical device approved by the U.S. Food and Drug Administration (FDA) in the United States for individualized weight loss for obese patients whose weight is affecting their health.
Earlier this month the company reported that fourth-quarter earnings climbed 6 percent, as sales for key products like Botox helped balance expense increases. On the downside, the company's obesity intervention segment has sales declining 23.0% to $46.9 million. In early February Allergan reported that it will halt the selling of its gastric banding device to a group of Southern California bariatric surgery centers.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer
- obesity epidemic